ICOCON: Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

Sponsor

Centre Hospitalier le Mans (Other)

Overall Status

Recruiting

CT.gov ID

NCT05062655

Collaborator

(none)

130

Enrollment

Location

Arms

16.2

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient.

Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity.

The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management.

This new organisation is part of the policy of continuous improvement of the quality and safety of care

Condition or Disease	Intervention/Treatment	Phase
Hospitalized Patient	Other: Drug reconciliation	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

130 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

Nterest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

Actual Study Start Date :

Aug 3, 2021

Anticipated Primary Completion Date :

Dec 8, 2022

Anticipated Study Completion Date :

Dec 8, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Drug reconciliation Drug reconciliation and transmission to pharmacist	Other: Drug reconciliation Drug reconciliation information transmission to pharmacist interview with the patient
No Intervention: standard

Arm

Intervention/Treatment

Experimental: Drug reconciliation

Drug reconciliation and transmission to pharmacist

Other: Drug reconciliation

Drug reconciliation information transmission to pharmacist interview with the patient

No Intervention: standard

Outcome Measures

Primary Outcome Measures

Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment [1 month after inclusion]
Value of coordinated pathway is evaluated by number of days of treatment interruption between patient discharge and provision of treatment to the patient

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

hospitalized patient
Patient with a drug treatment with a particular mode of supply
Paediatric patient or an adult patient.
First inpatient stay over the inclusion period from late 2021 to late 2022

Exclusion Criteria:

Patient under curatorship or guardianship
Patient residing abroad
No free, informed and written consent obtained

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Centre Hospitalier Du Mans	Le Mans		France	72000

Sponsors and Collaborators

Centre Hospitalier le Mans

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Centre Hospitalier le Mans

ClinicalTrials.gov Identifier:

NCT05062655

Other Study ID Numbers:

CHM-2021/S21/09

First Posted:

Sep 30, 2021

Last Update Posted:

Jan 24, 2022

Last Verified:

Sep 1, 2021

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Centre Hospitalier le Mans

Medication reconciliation

Continuity

Town-hospital network

Study Results

No Results Posted as of Jan 24, 2022